ACM
LXRX icon

ADAR1 Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

ADAR1 Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.8M Hold
750,000
– – 0.08% 144
2026
Q1 		$1.17M Buy
+750,000
New +$1.09M 0.07% 145

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

ADAR1 Capital Management's LXRX Position: Q2 2026 in Review

ADAR1 Capital Management held its Lexicon Pharmaceuticals (LXRX) position steady in Q2 2026 at 750,000 shares worth $1.8M. The position accounts for 0.08% of the portfolio, ranked #144.

ADAR1 Capital Management first reported a position in LXRX in Q1 2026 and has held it in 2 quarters since. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • ADAR1 Capital Management held 750,000 shares of Lexicon Pharmaceuticals worth $1.8M as of Q2 2026.
  • ADAR1 Capital Management left its Lexicon Pharmaceuticals share count unchanged in Q2 2026.
  • Lexicon Pharmaceuticals made up 0.08% of ADAR1 Capital Management's portfolio in Q2 2026, its #144 holding.
  • ADAR1 Capital Management first reported a position in Lexicon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.